1. Introduction {#sec1}
===============

A better pathophysiologic knowledge and the apparition of international recommendations allowed an improvement of septic shock\'s prognosis, but mortality still remains above 50% \[[@B1], [@B2]\]. Numerous factors are associated to mortality in septic shock. Early recognition of these factors can help to identify the most critical situations and to provoke a more aggressive resuscitation. We realized an observational study including all the patients suffering from septic shock and hospitalized in our intensive care unit (ICU) from 2003 to 2007. Beyond an epidemiologic analysis, we wanted to identify mortality risk factors and evolution of septic shock management in our ICU.

2. Material and Methods {#sec2}
=======================

2.1. Inclusion Criteria and Study Aims {#sec2.1}
--------------------------------------

We included all the patients suffering from septic shock and hospitalized in the ICU of Tourcoing hospital, France, between January 2003 and January 2008. Our study had 3 aims: an epidemiologic record, the identification of independent mortality risk factors, and the evaluation of management and prognosis comparing 2 periods, before and after the publication of the Surviving Sepsis Campaign (SSC) international guidelines in December 2004 \[[@B3]\].

2.2. Data Collection and Definitions {#sec2.2}
------------------------------------

### 2.2.1. On Admission {#sec2.2.1}

For all patients, the following characteristics were prospectively collected on ICU admission: age, gender, underlying clinical conditions, severity of illness, and vital sign abnormalities. Severity of illness was assessed by the Simplified Acute Physiology Score (SAPS) II \[[@B4]\] and the Sepsis-related Organ Failure Assessment (SOFA) score \[[@B5]\]. We estimated an organ dysfunction if the score for this organ was superior to 3. Septic shock was defined as a sustained (≥1 h) decrease in the systolic blood pressure of at least 40 mmHg from baseline or a resultant systolic blood pressure \<90 mmHg after adequate fluid replacement and in the absence of any antihypertensive drug \[[@B6]\]. We recorded the community or hospital-acquired origin of the infection, bacteriological data and if the patient presented coinfection (more than one pathologic bacteria recovered). We also noted the delay from the hospital admission, from the onset of the sepsis and the septic shock, to the admission in the ICU. We recorded all the bacteriological samples as well as the initial antibiotic therapy. Antibiotic therapy was defined as adapted (if it followed recommendations), and adequate (if it comported at least one antibiotic active in vitro on the causal bacteria). Delay from the onset of the sepsis to the start of the antibiotic treatment was also noted.

Volume expansion with hydroxyethylstarches (HES), cristalloids, 4% albumin and packed red blood cells was quantified at 6 and 24 hours after the onset of the sepsis as well as vasopressor use. We also recorded the use of activated protein C, hydrocortisone, intensive insulin therapy, type and amount of nutrition, need for mechanical ventilation or renal replacement therapy (RRT). We also noted the time from the beginning of vasopressors and the prescription of hydrocortisone, nutrition, ventilation, and RRT.

### 2.2.2. Evolution {#sec2.2.2}

We recorded if the patients presented a recurrence of shock (need for vasopressor after 8 hours weaning). During the ICU stay, occurrence of complications was recorded. We distinguished infection-related complications (acute respiratory distress syndrome (ARDS), acute renal failure, disseminated intravascular coagulation, and acute hepatic failure) and hospital-acquired infections. Finally, we recorded the number of days alive free from mechanical ventilation, vasopressors, and RRT on day 28. Mortality was evaluated on day 28 and at ICU discharge.

2.3. Statistical Analysis {#sec2.3}
-------------------------

To determine the factors associated with mortality, we realized a logistic regression analysis. First, we performed a monovariate analysis, and then pooled the significant parameters (*P* \< .2) in a multivariate analysis with the estimate of the Odds Ratio (OR). For multivariate analysis, an area under the curve was used to determine the cut-off of continuous variables. Comparisons between groups were performed using Chi-square test or Fisher\'s exact test for categorical parameters. Continuous variables were analysed using Wilcoxon\'s test. Differences between groups were considered to be significant for variables yielding a *P*  value \< .05. All analyses were performed using the SAS Software, V8.2.

3. Results {#sec3}
==========

3.1. Baseline Characteristics on Admission {#sec3.1}
------------------------------------------

Between January 2003 and January 2008, 320 patients were hospitalized in our ICU for septic shock. Sixty three percent of the population was male, mean age was 65 ± 15.3 years, SAPS II and SOFA score were 62.3 ± 20.1 and 11.3 ± 3.2, respectively. The major comorbidity was chronic alcoholism (26.8%), followed by chronic obstructive pulmonary disease (COPD (25.2%)), diabete mellitus (21.8%), and chronic cardiac failure (18%). Associated organ failures were respiratory (83.6%), neurologic (35.7%), renal (26.3%), coagulation (15.2%), and hepatic (3.5%). Mean times from the hospital admission, the onset of the sepsis and the septic shock to ICU admission were 3.8 ± 7.5 days, 16.7 ± 28.8 hours, and 2.4 ± 4.8 hours, respectively.

3.2. Bacteriology and Antibiotic Therapy {#sec3.2}
----------------------------------------

The sepsis was community-acquired in 64% of the patients. Infectious site was predominantly respiratory (48.4%), followed by intraabdominal (20%) and urinary (8.7%). The infection was bacteriologically documented in 59% of the patients, with 33% of positive blood cultures. 20.4% of the patients presented coinfections. Causative pathogens were Gram-positive cocci in 45.3% of the positive cultures, mostly represented by *Streptococcus pneumoniae* (17.4%) and *Staphylococcus aureus* methicillin-sensitive (11.6%), and methicillin-resistant (4.2%). Gram-negative bacilli were found in 43.2%: *Escherichia coli* (15.8%), *Klebsiella* (5.3%), and *Pseudomonas aeruginosa* ticarcillin-sensitive (4.7%) and ticarcillin-resistant (3.7%). Anaerobes bacteria represented 3.7% and Candida 2.6% of the cases. Mean time from the onset of the sepsis to the introduction of antibiotics was 9.8 ± 18.7 hours. It was adapted in 97% and adequate in 88% of the patients.

3.3. Management {#sec3.3}
---------------

Mean plasma volume expansion during the 24 hours following the sepsis was 1160 ± 793 mL for HES and 2194 ± 1720 mL for cristalloids. The most used vasopressor agent was norepinephrine in 74%, followed by dopamine (42%), dobutamine (26%), and epinephrine (16%). Only 7% of the patients received activated protein C. Hydrocortisone was prescribed in 84% of the population, 7.9 ± 12 hours after the onset of shock. Mechanical ventilation was needed in 88%; noninvasive ventilation was performed in 13% of the patients. Thirty one percent of the patients needed RRT.

3.4. Prognosis on Day 28 {#sec3.4}
------------------------

Recurrence of shock was noted in 24% of the population, complications of septic shock in 28.2% and hospital-acquired infections in 25.7% with 32% of multiresistant bacteria. ICU mortality was 54.4%, day 28 mortality 51.2%. Time alive free from ICU, mechanical ventilation, vasopressors, and RRT on day 28 was 5.6 ± 8.8 days, 5.3 ± 8.4 days, 10.1 ± 10.5 days and 9 ± 11.2 days, respectively.

3.5. Independent Mortality Risk Factors {#sec3.5}
---------------------------------------

For all the collected variables, we realized a bivariate analysis ([Table 1](#tab1){ref-type="table"}), and then all the significant parameters were entered in a multivariate analysis. We found 6 independent variables associated with mortality: need for mechanical ventilation, SAPS II \>60, chronic alcoholism, age \>65 years, prothrombin ratio (PR) \<40% and PaO~2~/FiO~2~\<150 ([Table 2](#tab2){ref-type="table"}).

3.6. Comparison of the 2003-2004 and 2005--2007 Periods {#sec3.6}
-------------------------------------------------------

The 2003-2004 period represented 41.9% of the population. The 2 groups were homogeneous for baseline characteristics except more chronic cardiac failures (27.8% versus 10.8%, *P* = .001) and a lower SOFA score (10.9 ± 3.2 versus 11.6 ± 3.2, *P* = .0338) during the 2003-2004 period. In contrast, the management of the 2 groups was very different: in the second period, norepinephrine became the vasoactive agent of choice (*P* \< .0001) instead of dopamine and dobutamine, initial plasma volume expansion was greater (*P* = .0005), patients received more intensive insulin therapy (*P* \< .0001), and the delays of intubation (*P* = .01), antibiotic therapy (*P* = .0037), initiation of hydrocortisone (*P* = .0001), RRT (*P* = .002), and nutrition (*P* = .0389) were shortened ([Table 3](#tab3){ref-type="table"}).

Prognosis variables were also different between the 2 periods. We found during the period 2005--2007 an increase in the number of days alive free from mechanical ventilation (*P* = .0207) and vasopressors (*P* = .0021) on day 28, and a decrease in septic shock complications (*P* \< .0001). However, there was no difference in mortality (*P* = .79). All the significant differences concerning the prognosis are presented [Table 4](#tab4){ref-type="table"}.

4. Discussion {#sec4}
=============

4.1. Epidemiology and Prognosis {#sec4.1}
-------------------------------

Mean age was 65 years and there was a predominance of male. Three French epidemiologic studies found a similar repartition \[[@B1], [@B2], [@B7]\]. In contrast, our population was particularly severely ill; mean SAPS II and SOFA scores on admission were 62 and 11, respectively, compared to 58 and 9 in these studies \[[@B1], [@B2]\]. The infection was bacteriologically proven in 59% of the patients, as in the other studies \[[@B2], [@B8], [@B9]\]. Literature data also reveal a change in the origin of the sepsis with a decrease of intraabdominal and Gram-negative bacilli infections replaced by pulmonary and Gram-positive cocci infections \[[@B10]--[@B12]\]. It is in accordance with our results: half of the infections was coming from the respiratory tract and was caused by Gram-positive cocci. Annane, realizing a multicenter epidemiologic study between 1993 to 2000 found a 60.1% mortality rate, with an improvement from 1993 (62.1%) to 2000 (55.6%) \[[@B2]\]. This improvement seems to be related to an earlier and more aggressive management and an improvement in specific anti-infectious therapies \[[@B13]--[@B15]\]. ICU mortality in our study was 54.4%. Most other published studies found a 35% mortality rate, but patients with severe sepsis were also included \[[@B1], [@B10], [@B16]--[@B18]\].

We recovered six independent mortality risk factors: mechanical ventilation, SAPS II \>60, chronic alcoholism, age \>65 years, PR \<40%, and PaO~2~/FiO~2~ ratio \<150. These factors can easily be available on admission and allow screening immediately a group of patients with a high mortality risk. Our results confirm the classic risk factors associated with mortality recovered in the literature \[[@B1], [@B2], [@B7], [@B10]\]. Specifically regarding chronic alcoholism, numerous studies report its association with the frequency of infections \[[@B19], [@B20]\], but an important role in mortality in the absence of hepatic failure is not well known, excepted in the study by O\'Brien \[[@B21]\] who found an increase in mortality in ICU patients suffering from chronic alcoholism, and particularly when patients developed severe sepsis and septic shock. Its deleterious effect was probably revealed by the high prevalence of alcoholism in our population (26.8%).

Most shocking is the absence of signification of antibiotic therapy. Numerous studies \[[@B9], [@B22], [@B23]\] showed an impairment of the prognosis when antibiotic therapy was delayed. In particular, Kumar found a 7.6% increased mortality for each hour delay of antibiotics \[[@B24]\]. Mean time for antibiotic therapy in our study was very long (9.77 hours), but it was calculated from the onset of the sepsis and not septic shock. Adequate antibiotic therapy improves the prognosis of patients suffering from septic shock. In our study, antibiotic therapy was adapted in 97% of the patients and adequate in 88%. These results are excellent, compared, for example, to a 2003 american study who found 23% of nonadapted antibiotic therapy, responsible of an increase in mortality \[[@B9]\]. These important percentages probably explain the absence of signification of antibiotics in our study.

4.2. Comparison of 2003-2004 and 2005--2007 Periods {#sec4.2}
---------------------------------------------------

In spite of a higher SOFA score during the 2005--2007 period, the mortality remained the same but some variables improved (diminution of septic shock complications, increase of the number of days alive free from mechanical ventilation and vasopressors on day 28). We tried to find if the evolution in the management of our patients could explain these differences. The first hours are critical in septic shock and the major difference in the management between the 2 periods was the rapidity to institute all medical or replacement therapies. Likewise, initial plasma volume expansion was greater in the last period. Nevertheless, these volumes of fluids (about 3.5 litres in 24 hours) are far below others studies where patients received nearly 5 or 6 litres \[[@B1], [@B3], [@B7], [@B11], [@B12], [@B14], [@B23]\]. The aggressive 〈〈  early  goal  directed  therapy  〉〉 \[[@B14]\] is recommended by the SSC \[[@B3]\], because of its beneficial effect on mortality. Even with an increase in plasma volume expansion between the 2 periods, it remains probably too low. This is well explained by the difficulty to translate prospective controlled studies in daily clinical practice. Moreover, we collected the data from the onset of the sepsis when patients were often hospitalized in other units and physicians who are not intensivists are not sensitized to the importance of an aggressive volume expansion.

Regarding the hemodynamic support, norepinephrine became the vasopressor of choice in replacement of dopamine. Likewise, the dobutamine was used very often before 2005 and its indication was restricted after. This is conforming to the recommendations of the SSC \[[@B3]\]. Activated protein C is a controversial treatment of septic shock and is not a high grade recommendation in the 2008 SSC \[[@B25]\]. Waiting for the results of ongoing studies, we do not often use this molecule (4.5% and 8.1% of the patients during the 2 periods), so we cannot evaluate it in our study. Hydrocortisone was largely used during the 2 periods (80.6% and 87.1%), following the study published by Annane in 2002 \[[@B26]\]. Finally, the 2004 recommendations \[[@B3]\] have contributed to introduce more intensive insulin therapy in our ICU. Van den Berghe et al. \[[@B27]\] have demonstrated in 2001 a reduction of mortality in surgical patients when maintaining glycaemia between 0.8 to 1.1 g/l with a decrease in multiorgan failures secondary to septic shock. The same team \[[@B28]\] did not confirm their results in a population of medical patients and the study recently published by Arabi do not support this intensive strategy \[[@B29]\]. In our study, we did not find deleterious effect of insulin, but we did not recorded hypoglycaemia.

5. Conclusion {#sec5}
=============

The six mortality risk factors recovered in the multivariate analysis can easily be available on admission and allow screening immediately a group of patients with a high mortality risk. Concerning the evolution of the management during these 5 years, even if it is difficult in usual practice to be completely in accordance with recommendations, we remark an earlier introduction of numerous replacement and medical therapies as well as a more initial aggressive volume expansion. This probably explains the improvement in morbidity, whereas mortality did not change.

###### 

Mortality risk factors in septic shock patients: monovariate analysis COPD: chronic obstructive pulmonary disease, SAPS: simplify acute physiology score, SOFA: sepsis-related organ failure assessment score, ICU: intensive care unit, RRT: renal replacement therapy, prothrombin ratio (PR).

                                                                        Survivors 146 (45.6)   Deceased174 (54.4)   *P*
  --------------------------------------------------------------------- ---------------------- -------------------- ---------
  *Comorbidities* *n*(*%)*                                                                                          
  Chronic cardiac failure                                               21(14.4)               36(21)               .1233
  Diabete mellitus                                                      29(19.9)               40(23.4)             .4479
  COPD                                                                  35(23.9)               45(26.3)             .6321
  Chronic liver failure                                                 11(7.5)                24(14)               .0656
  Chronic alcoolism                                                     28(19.1)               57(33.3)             .0046
  Chronic renal failure                                                 6(4.1)                 10(5.8)              .4810
  Non hematologic malignancy                                            16(10.9)               20(11.6)             .8367
  Hematologic malignancy                                                16(10.9)               16(9.3)              .6369
  Immunosuppression                                                     25(17.1)               24(14)               .4484
  *Clinical presentation*                                                                                           
  Male sex *n*(%)                                                       92(63)                 111(63.8)            .8853
  Age (years) (mean ± SD)                                               61.6 ± 15.5            68.5 ± 14.3          \<.0001
  Lactate (meq/l) (mean ±  SD)                                          3 ± 2.2                4.9 ± 4              \<.0001
  Platelet count (1000/mm³) (mean ± SD)                                 203 ± 144              198 ± 143            .7813
  Creatinine (mg/l) (mean ± SD)                                         21.6 ± 15.4            22.7 ± 12.3          .4825
  Bilirubine (mg/l) (mean ± SD)                                         14.2 ± 13.5            20.6 ± 27.4          .0157
  PR (%) (mean ± SD)                                                    58.6 ± 19.8            49.6 ± 20.5          \<.0001
  pH (mean ± SD)                                                        7.3 ± 0.1              7.2 ± 0.1            .0007
  PaO~2~/FiO~2~ (mean ± SD)                                             190 ± 103              154 ± 101            .0021
  SAPS II (mean ± SD)                                                   52.7 ± 13.9            70.3 ± 20.9          \<.0001
  SOFA score (mean ± SD)                                                10.6 ± 3               11.9 ± 3.1           .0002
  Respiratory failure *n*(%)                                            123(84.2)              153(88.4)            .2746
  Renal failure *n*(%)                                                  30(20.5)               53(31.1)             .0323
  Coagulation failure *n*(%)                                            21(14.3)               29(17.2)             .4869
  Hepatic failure *n*(%)                                                1(0.7)                 10(6)                .0108
  Neurologic failure *n*(%)                                             40(28.5)               70(41.6)             .0169
  *Management*                                                                                                      
  Time from shock to ICU admission (hours) (mean ± SD)                  2.5 ± 5.6              2.2 ± 4              .6034
  Adapted antibiotic therapy *n*(%) (mean ± SD)                         138(97.8)              154(96.8)            .7269
  Time from sepsis to adapted antibiotic therapy (hours) (mean ± SD)    8 ± 18.2               11.2 ± 19            .1426
  Adequate antibiotic therapy *n*(%)                                    89(92.7)               76(83.5)             .0512
  Time from sepsis to adequate antibiotic therapy (hours) (mean ± SD)   10.3 ± 23.3            15.4 ± 25.7          .1698
  Mechanical ventilation *n*(%)                                         116(79.4)              166(95.9)            \<.0001
  Noninvasive ventilation *n*(%)                                        12(8.6)                27(15.6)             .0614
  Time from shock to intubation (hours) (mean ± SD)                     2.5 ± 6.4              3.3 ± 9.8            .4050
  RRT *n*(%)                                                            41(28)                 57(33.1)             .3304
  Time from shock to RRT (hours) (mean ± SD)                            29 ± 38.7              29.7 ± 33.4          .9216
  Cristalloid volume expansion at 6 hours of sepsis (mL) (mean ± SD)    1302 ± 1123            974 ± 1127           .0135
  Cristalloid volume expansion at 24 hours of sepsis (mL) (mean ± SD)   2629 ± 1748            1842 ± 1618          \<.0001
  Hydrocortisone *n*(%)                                                 123(84.2)              147(84.4)            .9538
  Time from shock to initiation of hydrocortisone (hours) (mean ± SD)   8.2 ± 13               7.4 ± 10.9           .5985
  Activated proteine C *n*(%)                                           13(8.9)                8(4.6)               .1246
  Intensive insulin therapy *n*(%)                                      94(64.3)               86(49.4)             .0072
  Enteral nutrition *n*(%)                                              101(70.6)              67(51.1)             .0009
  Parenteral nutrition *n*(%)                                           39(27.2)               29(22.1)             .3256
  Time from shock to initiation of nutrition (days) (mean ± SD)         2.5 ± 1.3              2.4 ± 1.1            .7918

###### 

Independent mortality risk factors in septic shock patients: multivariate analysis SAPS: simplify acute physiology score, prothrombin ratio (PR).

                           Odds ratio   Confidence interval   *P*
  ------------------------ ------------ --------------------- --------
  Mechanical ventilation   4.97         \[1.79--13.75\]       .0021
  SAPS II \>60             4.28         \[2.51--7.13\]        .0001
  Chronic alcoholism       3.38         \[1.75--6.52\]        .0003
  Age \>65 years           2.65         \[1.47--4.79\]        .0012
  PR \<40%                 2.37         \[1.26--4.45\]        .0074
  PaO~2~/FiO~2~\<150       1.91         \[1.15--3.26\]        .00183

###### 

Baseline characteristics and management of septic shock patients: significant differences between the 2003-2004 and 2005--2007 periods. COPD: chronic obstructive pulmonary disease, SAPS: simplify acute physiology score, SOFA: sepsis-related organ failure assessment score, ICU: intensive care unit, RRT: renal replacement therapy, prothrombin ratio (PR).

                                                                         2003-2004      2005--2007      *P*
  ---------------------------------------------------------------------- -------------- --------------- ---------
  *Comorbidities n(%)*                                                                                  
  Chronic cardiac failure                                                37(27.8)       20(10.8)        .001
  Diabete mellitus                                                       34(25.6)       35(19)          .16
  COPD                                                                   39(29.3)       41(22.3)        .1544
  Chronic liver failure                                                  19(14.3)       16(8.7)         .1171
  Chronic alcoolism                                                      (24.8)         (28.3)          .4939
  Chronic renal failure                                                  8(6)           8(4.3)          .5034
  Non hematologic malignancy                                             8(6)           28(15.2)        .8367
  Hematologic malignancy                                                 18(13.5)       14(7.6)         .084
  Immunosuppression                                                      18(13.5)       31(16.8)        .4205
  *Clinical presentation*                                                                               
  Male sex *n*(%)                                                        82(61.2)       121(65)         .4794
  Age (years) (mean ± SD)                                                63.9 ± 15.2    66.5 ± 15.3     .1374
  Lactate (meq/l) (mean ± SD)                                            4.6 ± 4.1      3.7 ± 2.9       .0993
  Platelet count (1000/mm³) (mean ± SD)                                  180 ± 1410     215 ± 144       .0345
  Creatinine (mg/l) (mean ± SD)                                          22.4 ± 14.6    22.1 ± 13.3     .8113
  Bilirubine (mg/l) (mean ± SD)                                          20.8 ± 21.1    15.4 ± 22.4     .0425
  PR (%) (mean ± SD)                                                     52.1 ± 21.5    55.1 ± 20.1     .2117
  pH (mean ± SD)                                                         7.29 ± 0.14    7.29 ± 0.13     .7409
  PaO~2~/FiO~2~ (mean ± SD)                                              161.1 ± 96.4   177.9 ± 107.9   .1649
  SAPS II (mean ± SD)                                                    60.8 ± 20.1    63.4 ± 20.1     .259
  SOFA score (mean ± SD)                                                 10.9 ± 3.2     11.6 ± 3.2      .0338
  *Management*                                                                                          
  Mechanical ventilation *n*(%)                                          (85.1)         (90.8)          .1143
  Norepinephrine *n*(%)                                                  79(59)         158(85.4)       \<.0001
  Dobutamine *n*(%)                                                      51(38.1)       32(17.4)        \<.0001
  Dopamine *n*(%)                                                        91(67.9)       43(23.4)        \<.001
  Intensive insulin therapy *n*(%)                                       17(12.7)       163(87.6)       \<.0001
  Time from sepsis to adapted antibiotic treatment (hours) (mean ± SD)   13.9 ± 18.7    7.2 ± 18.3      .0037
  Cristalloid volume expansion at 6 hours of sepsis (mean ± SD)          816 ± 1038     1323 ± 1155     .0001
  Cristalloid volume expansion at 24 hours of sepsis (mean ± SD)         1773 ± 1674    2479 ± 1696     .0005
  Time from shock to initiation of hydrocortisone (hours) (mean ± SD)    11.3 ± 14      5.6 ± 9.8       .0001
  Time from shock to intubation (hours) (mean ± SD)                      4.6 ± 11.9     1.9 ± 5.2       .0105
  Time from shock to RRT (hours) (mean ± SD)                             43.6 ± 42      20.8 ± 28.1     .002
  Time from shock to initiation of nutrition (days) (mean ± SD)          2.7 ± 1.4      2.3 ± 1.1       .0389

###### 

Prognosis of septic shock patients: comparison between the 2003-2004 and 2005--2007 periods. ICU: intensive care unit, RRT: renal replacement therapy.

                                                                                2003-2004    2005--2007    *P*
  ----------------------------------------------------------------------------- ------------ ------------- ---------
  Septic shock complications *n*(%)                                             60(46.5)     29(15.6)      \<.0001
  Number of days alive free from mechanical ventilation on day 28 (mean ± SD)   3.9 ± 6.9    6.2 ± 9.1     .0207
  Number of days alive free from vasopressors on day 28 (mean ± SD)             8 ± 9.6      11.6 ± 10.9   .0021
  Number of days alive free from RRT on day 28 (mean ± SD)                      8.6 ± 12.1   9.2 ± 10.7    .76
  Patients discharged from ICU on day 28 *n*(%)                                 46(34.6)     69(37.1)      .6452
  ICU death *n*(%)                                                              74(55.2)     100(53.8)     .7958
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